Vera Therapeutics, Inc.
VERA
$34.26
-$1.02-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 144.59% | 151.87% | 144.44% | 155.38% | 125.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.13% | 98.40% | 88.71% | 85.97% | 101.34% |
| Operating Income | -76.13% | -98.40% | -88.71% | -85.97% | -101.34% |
| Income Before Tax | -84.12% | -110.28% | -96.92% | -87.49% | -102.40% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -84.12% | -110.28% | -96.92% | -87.49% | -102.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.12% | -110.28% | -96.92% | -87.49% | -102.39% |
| EBIT | -76.13% | -98.40% | -88.71% | -85.97% | -101.34% |
| EBITDA | -76.12% | -98.31% | -88.55% | -85.77% | -101.16% |
| EPS Basic | -63.93% | -85.07% | -70.12% | -53.30% | -62.35% |
| Normalized Basic EPS | -63.69% | -84.79% | -70.01% | -53.30% | -62.35% |
| EPS Diluted | -63.93% | -85.07% | -70.12% | -53.30% | -62.35% |
| Normalized Diluted EPS | -63.69% | -84.79% | -70.01% | -53.30% | -62.35% |
| Average Basic Shares Outstanding | 12.23% | 13.14% | 16.11% | 22.90% | 24.95% |
| Average Diluted Shares Outstanding | 12.23% | 13.14% | 16.11% | 22.90% | 24.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |